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Objectives: In Type 1 diabetic (T1D) patients high values of glycated hemoglobin 
(HbA1c) have been shown to be associated with higher risk of complications 
leading to high costs to the National Health Care System (NHS). The aim of this 
analysis is to evaluate the economic impact of poor glycaemic control, and the 
potential savings associated with better glycemic control in the Italian T1D popula-
tion. MethOds: A probabilistic model using published risk-curves was developed 
to project incidence and progression of diabetes-related complications associated 
with different HbA1c levels over 1-year and 5-year time-horizon in T1D patients. 
Associated cost of retinopathy, nephropathy, neuropathy, cardiovascular disease, 
diabetic ketoacidosis and severe hypoglycemia in the Italian setting were used to 
estimate the economic impact of complications in each HbA1c interval form the 
NHS perspective. Subsequently the results of the simulation were translated to 
the entire Italian T1D population stratified by HbA1c level accordingly to published 
2012 data. Results: Estimated cost per patients of diabetes-related complica-
tions in the first year of occurrence, stratified by HbA1c intervals, ranged from 
4,463€ for HbA1c ≥ 10% to 2,006€ for HbA1c between 7% and 8%. A 5 year follow 
up analysis was also conducted. A treatment strategy able to reduce HbA1c level 
from ≥ 10% to 9% could lead to potential savings of 1,342€ per patients in the first 
year of treatment. Considering the total T1D Italian population, improving HbA1c 
to < 8% in the first year would results in a potential savings of about 17 million 
euros. cOnclusiOns: The economic impact of diabetes-related complications in 
the Italian setting is significant. Consequently the potential savings for the NHS 
derived from the implementation of strategies aimed at improving HbA1c in T1 
should be considered. Moreover the greater the reduction of Hba1c obtained the 
greater the associated savings.
PDB25
Cost-ComParison Between Different treatment regimens in DiaBetes 
mellitus in germany BaseD on long aCting insulins
Anderten H.1, Dippel F.W.2, Schneider T.2
1Ambulatory Care, Hildesheim, Germany, 2Sanofi, Berlin, Germany
Objectives: Cost comparison between different basal insulin regimens (Glargine 
vs. Detemir vs. NPH-insulin) in diabetic patients in Germany under real-life condi-
tions. MethOds: The analysis is based on IMS LRx-database (2011). This repre-
sentative patient tracking tool covers nearly 60 million insurants and includes 
more than 500 million drug prescriptions per year (including consumables) 
Patients with at least two prescriptions of basal insulin (Glargine, Detemir or 
NPH-insulin) in 2011 (January – December) and at least one prescription of any 
type in 2010 and 2012 were considered eligible. Costs included basal and bolus 
insulin, oral antidiabetic drugs, test strips, needles and lancets and were esti-
mated by ex pharmacy prices (Lauer Taxe) minus legally defined rebates according 
to §130 a of social security code (SGB V). Results: A total of 542.438 patients 
were allocated to either Glargine (207.506 patients) or Detemir (90.671 patients) 
or NPH (244.261 patients). The mean annual treatment costs per patient are 1.211 
€ (Glargine), 1.224 € (NPH insulin) and 1.572 € (Detemir). A breakdown at the level 
of different sick funds shows a similar pattern of annual treatment costs per 
patient of the three basal insulin regimens. The acquisition costs of basal insu-
lin is considerably higher for Glargine (380 € ) and Detemir (448 € ) compared to 
NPH-Insulin (253 € ). The cost of bolus insulin is lower in the Glargine group (305 
€ ) compared to NPH-insulin (419 € ) and Detemir (493 € ). Costs of consumables 
(test strips, needles, lancets) are lowest in the in the Glargine group (395 € ) due 
fewer insulin applications compared to Detemir (509 € ) and NPH insulin (461 
€ .) cOnclusiOns: Mean annual treatment costs are lowest with Glargine fol-
lowed by NPH-insulin, whereas Detemir based regimens are 30% more expensive 
under real life conditions. The results are in line with previous cost analyses in 
diabetic patients in Germany [1-3]
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Objectives: To assess the economic burden and health care utilizations of 
diabetes in the U.S. veteran population. MethOds: Adult (≥ 18 years of age) 
patients diagnosed with diabetes (International Classification of Disease 9th 
Revision Clinical Modification [ICD-9-CM] code 250.x0 or 250.x2) were identi-
fied from the dataset between October 1, 2009 through September 30, 2011. The 
first diagnosis date was designated as the index date. A comparator group was 
created consisting of patients without diabetes but of the same age, region, 
gender and index year, and matched by baseline Charlson Comorbidity Index. 
The index date for the comparator group was randomly selected to minimize 
selection bias. Continuous medical and pharmacy benefits 1 year pre- and 1 year 
post-index date were required for patients in both groups. One-to-one propensity 
score matching (PSM) was applied to compare health care costs and utiliza-
tions during the follow-up period between the diabetes and comparator groups, 
adjusted for baseline demographic and clinical characteristics. Results: A total 
of 1,427,948 patients were identified for the diabetes and comparator cohorts. 
After applying 1:1 PSM matching, a total of 340,933 patients were matched from 
each group, ensuring well-balanced baseline characteristics. Patients diagnosed 
with diabetes were more likely to report inpatient (8.93% vs. 2.09%, p< 0.01), emer-
gency room (13.66% vs. 5.61%, p< 0.01), outpatient (99.63% vs. 53.78%, p< 0.01), 
and pharmacy visits (87.13% vs. 52.69%, p< 0.01). They also incurred higher 
health care costs, including inpatient ($3,031 vs. $582, p< 0.01), emergency room 
($137 vs. $51, p< 0.01), outpatient ($3,375 vs. $1,272, p< 0.01), pharmacy ($708 vs. 
$293, p< 0.01) and total costs ($7,113 vs. $2,148, p< 0.01) than the comparator 
group. cOnclusiOns: U.S. veteran patients diagnosed with diabetes reported 
a significantly higher economic burden compared to the matched controls over 
a 12-month period.
observational studies and Centre for Evidence Based Medicine checklists for any 
other study design. The present review is part of the GIFTS project funded by Seventh 
Framework Programme of European Commission. Results: A total of 349 papers 
were identified, after title and abstract revision 76 full text were retrieved plus 8 
identified through pearling. To date 67 full texts have been assessed, 49 excluded and 
18 included. 14 (78%) were conducted in the UK. South Asian pregnant women were 
at higher risk of developing GDM (OR ranged 2-5.6) and intrauterine growth retarda-
tion (OR ranged 2-5) than European counterparts. These factors contributed to higher 
rates of stillbirth, perinatal and neonatal mortality and congenital anomalies detected 
in South Asian origin women. As well as higher rates of babies with vitamin D defi-
ciency, hypocalcaemia, hyperinsulinemia, dyslipidaemia, hypoglycaemia and lower 
birthweight. Also higher risk of rapid weight gain between 12 to 24 months and 3 to 
5 years in Asian infants was reported in two different papers. cOnclusiOns: There 
are differences between Asian women living in Europe and European women during 
pregnancy, and their offspring, which as early life factors might explain higher preva-
lence of later metabolic syndrome and type 2 diabetes in Asian migrant population.
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Objectives: Recent studies have quantified the resource implications associated 
with severe hypoglycaemia episodes (SHE) and non-severe hypoglycaemia episodes 
(NSHE). The objective of this study was to characterize the relationship between the 
frequency of SHE/NSHE and patient/therapy characteristics in insulin treated type-2 
diabetes mellitus (T2DM) patients. MethOds: We conducted a literature review of 
the MEDLINE database for insulin-based T2DM clinical trials where sulfonylurea usage 
was also reported between June 1, 2007 and June 1, 2012. Patient demographics, treat-
ments effects and treatment type were extracted and the SHE/NSHE rate per 100 
patient years (PY) was modeled via a log-linear regression model using R. Results: 
Data were extracted from 82 studies for a total of 155 trial arms meeting the search 
criteria; treatment regimes were categorized into basal analog (30%); bolus analog 
(4%); basal bolus (24%); biphasic analog (25%); biphasic human (8%) and NPH (10%). 
Mean (standard deviation) age was 57.9 (3.8) years; 10.2 (2.4) years duration of diabe-
tes; 8.8% (0.7)baseline and 7.5% (0.5) end-of-study HbA1c respectively. Mean reported 
NSHE/100 PYs was 929.8. The final regression model was NSHE/100PY= exp(14.771 
- 0.088 × age - 0.667 × baseline HbA1c + 0.427 × HbA1c reduction + 0.189 × duration 
diabetes + 0.007 × % study allowed sulphonylurea – 0.545 × basal analog insulin) with 
an R2 goodness of fit of 0.226. Mean reported SHE/100 PYs was 5.9. The final regression 
model was SHE/100PY= exp(10.794 - 0.101 × age - 0.723 × baseline HbA1c + 0.638 × 
HbA1c reduction + 0.163 × duration diabetes + 0.768 × biphasic insulin )-1 with an 
R2of 0.219. cOnclusiOns: This study provides a basis for predicting the number of 
SHE and NSHE in insulin treated T2DM subjects. When linked to resource and quality 
life, these equations may facilitate the improved estimation of the health economic 
burden associated with SHEs and NSHEs.
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Objectives: Severe (requiring assistance from another individual) hypoglycaemic 
events (SHEs) are important from both clinical and economic perspectives. The aim 
was to assess treatment-related SHEs risk in different treatment regimens in type 1 
and 2 diabetes. MethOds: Anti-diabetic treatments were stratified into six groups: 
basal-bolus (BB); basal in combination with oral therapy (BOT); insulin pumps; bipha-
sic insulin; sulfonylureas; other than SU oral antidiabetic drugs (OADs). Insulin treat-
ments were further split into analogues (IA) and human insulins (HI). The systematic 
review of Medline, EMBASE and Cochrane databases was conducted for recent (≤ 10 
years), large (n ≥ 100), observational studies. Data on time horizon, participants num-
ber and SHEs occurrence were extracted. Using a random effects Poisson model within 
MCMC framework we estimated the SHEs rates. Results: In the systematic review 
5220 publications were found, 525 full texts evaluated and 101 articles included (55 
trials). The following average SHE/year (No of studies; 95%CI) were estimated: Type 1: 
BB with IA as the basal component: 0.53 (7; 0.29–1.18); BB with HI: 1.10 (6; 0.58–2.71); 
pump treatment: 0.18 (14; 0.13–0.25); biphasic insulin: 1.10 (0.58–2.71). Type 2: BOT 
with IA as the basal component: 0.13 (11; 0.04–1.17); BOT with HI: 0.21 (7; 0.08–0.88); 
BB with IA: 0.01 (6; 0.003–0.25); BB with HI: 0.56 (3; 0.16–9.65); biphasic IA: 0.10 (12; 
0.05–0.26); biphasic HI: 0.20 (6; 0.07–0.93); sulfonylureas: 0.05 (6; 0.02–0.14); OADs: 0.01 
(0.001–0.008). The differences in the SHEs risk among regimens were significant at a 
95% level. cOnclusiOns: The SHEs risk differs in both type 1 and 2 diabetes across 
various treatment regimens. HI was found to increase the SHEs risk compared to IA. 
Limited availability of studies and heterogeneous data make it difficult to come up 
with precise rate estimation for typical anti-diabetic treatment regimens.
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